Unmet needs and barriers in venous thromboembolism education and awareness among people living with cancer: a global survey
N Potere, I Mahé, P Angchaisuksiri… - Journal of Thrombosis …, 2024 - Elsevier
Background Venous thromboembolism (VTE) is a major preventable cause of morbidity,
disability, and mortality in subjects with cancer. A global appraisal of cancer-associated VTE …
disability, and mortality in subjects with cancer. A global appraisal of cancer-associated VTE …
Edoxaban for 12 Versus 3 Months in Cancer-associated Isolated Distal Deep Vein Thrombosis According to Different Doses: Insights from the ONCO DVT study
R Chatani, Y Yamashita, T Morimoto… - European Heart …, 2024 - academic.oup.com
Abstract Background The ONCO DVT study revealed the superiority of 12-month relative to 3-
month edoxaban treatment for cancer-associated isolated distal deep vein thrombosis (DVT) …
month edoxaban treatment for cancer-associated isolated distal deep vein thrombosis (DVT) …
Anticoagulation in Patients with Isolated Distal Deep Vein Thrombosis: Bringing the Puzzle Together
Whether and how to prescribe anticoagulant treatment in patients with acute isolated distal
deep vein thrombosis (IDDVT) is a long-lasting, recurring, and debated issue. 1 IDDVT …
deep vein thrombosis (IDDVT) is a long-lasting, recurring, and debated issue. 1 IDDVT …